Disc Medicine, Inc. announced that it has raised $53.5 million in a round of funding led by returning investor Access Biotechnology on December 29, 2022. The transaction also included participation from returning investors Novo Holdings A/S,Atlas Venture L.P.,OrbiMed Advisors LLC,Arix Bioscience plc,5AM Venture Management, LLC,Rock Springs Capital Management LP and Janus Henderson Group plc.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 USD | -3.32% | -12.62% | -54.59% |
Apr. 08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
Apr. 02 | Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
31 USD | -1.96% | +1.90% | 5.1B | ||
26.4 USD | -3.32% | -12.62% | 674M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.59% | 674M | |
+1.03% | 43.84B | |
+5.74% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.55% | 18.18B | |
-2.97% | 12.29B | |
+26.30% | 12.29B | |
+6.91% | 11.15B |
- Stock Market
- Equities
- IRON Stock
- News Disc Medicine, Inc.
- Disc Medicine, Inc. announced that it has received $53.5 million in funding from a group of investors